Valeant Pharma (VRX) Misses Q2 EPS by 8c, Reaffirms Guidance; Will Divest Ruconest Rights in N.A.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results
August 9, 2016 6:00 AM EDT2016 Full Year Guidance Reconfirmed
LAVAL, Quebec, Aug. 9, 2016 /PRNewswire/ --
Total Revenues of $2.4 billion, a decrease of 11% versus the second quarter of 2015 GAAP EPS Â ($0.88) and Adjusted EPS (non-GAAP) Â $1.40 Cash Flow from Operations of $448 million, an increase of 9% versus the second quarter of 2015Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") today announced second quarter 2016 financial results.
"We continue to make progress towards stabilizing the... More
